H2A (CIT-013 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is developed as a research-grade biosimilar to CIT-013, targeting histone H2A, a core component of the nucleosome structure essential for DNA packaging and chromatin organization. H2A plays critical roles in gene regulation, DNA repair, and chromosome stability through its involvement in nucleosome assembly and chromatin remodeling. Post-translational modifications of H2A, including ubiquitination, phosphorylation, and acetylation, serve as key epigenetic marks that influence transcriptional activity and cellular responses to DNA damage. Aberrant H2A expression and modification patterns have been implicated in various cancers, neurodegenerative disorders, and developmental abnormalities, making it an important target for understanding disease mechanisms.

CIT-013 is an established research antibody widely used in epigenetics and chromatin biology studies. This biosimilar provides researchers with a reliable tool for investigating histone dynamics, chromatin structure, and epigenetic regulation in various experimental contexts. It supports studies examining nucleosome composition, histone variant distribution, and the role of H2A in cellular processes including transcription, replication, and DNA damage response pathways.